Evidence map›Paper›PMID 35582699›Full record

ArticleMedicine2022

[Systemic and extrapulmonary manifestations of COVID-19].

J Balsa Vázquez, D Alonso Menchén, M M Martín Lloréns, J Sanz Moreno

Abstract readEnglish Abstract
In one paragraph

Article in Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. [Linear power and mortality in COVID-19 respiratory difficulty syndrome].Revista medica del Instituto Mexicano del Seguro Social · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

J Balsa VázquezServicio de Medicina Interna. Hospital Universitario Príncipe de Asturias. Universidad de Alcalá. Alcalá de Henares. Madrid. España.
D Alonso MenchénServicio de Medicina Interna. Hospital Universitario Príncipe de Asturias. Universidad de Alcalá. Alcalá de Henares. Madrid. España.
M M Martín LlorénsServicio de Medicina Interna. Hospital Universitario Príncipe de Asturias. Universidad de Alcalá. Alcalá de Henares. Madrid. España.
J Sanz MorenoServicio de Medicina Interna. Hospital Universitario Príncipe de Asturias. Universidad de Alcalá. Alcalá de Henares. Madrid. España.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although fever and respiratory symptoms are the main clinical expression of COVID-19 disease, important extrapulmonary complications that affect the majority of the organs and systems may occur. Multisystemic involvement can mainly be attributed to the generalized location of ACE2 receptors throughout the body, which act as the main point of entry for the virus. Systemic manifestations may occasionally appear before the typical symptoms, although they generally occur later or are sequelae of the disease. Thromboembolic complications are concerning due to their frequency and severity; they are the result of a hypercoagulable state with multiple possible clinical manifestations. Cardiac, neurological, gastrointestinal, renal, endocrine-metabolic, skin, and ocular complications may occur. The manifestations and specific therapeutic aspects of COVID-19 disease in pregnant women as well as implications of the disease on children are discussed. The corresponding tests must be performed in all patients with a clinical suspicion of COVID-19 in order to confirm the diagnosis of the infection. The specific diagnostic tests that are indicative of involvement of different organs are guided based on clinical suspicion. These tests are conducted on an individual basis taking into account the isolation measures required and the severity of each case. Likewise, the corresponding treatment is administered according to criteria that generally similar to those for the general population.

Indexed as

ACE2 receptorsCOVID-19 infectionExtrapulmonary manifestationsMultisystemic involvement

Identifiers

PMID35582699
PMCPMC9097973

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.